Abivax (ABVX) EBITDA (2022 - 2026)

Abivax's EBITDA history runs 5 years deep, the most recent figure standing at -$65.8 million for Q1 2026.

• On a quarterly basis, EBITDA fell 32.59% year-over-year to -$65.8 million in Q1 2026; TTM through Mar 2026 was -$296.3 million, a 57.12% decrease from a year earlier, with the FY2025 full-year figure at -$286.5 million, down 52.99% from the prior year.
• EBITDA improved to -$65.8 million in Q1 2026 per ABVX's latest filing, from -$83.5 million in the prior quarter.
• Across five years, EBITDA topped out at -$38.0 million in Q2 2024 and bottomed at -$137.1 million in Q4 2023.
• The 5-year median for EBITDA is -$55.1 million (2024), against an average of -$67.0 million.
• Across the five-year window, EBITDA slumped 107.34% in 2023 and soared 66.62% in 2024, its largest moves.
• Year by year, EBITDA stood at -$66.1 million in 2022, then tumbled by 107.34% to -$137.1 million in 2023, then surged by 66.62% to -$45.8 million in 2024, then tumbled by 82.41% to -$83.5 million in 2025, then climbed by 21.12% to -$65.8 million in 2026.
• Per Business Quant, the three latest ABVX EBITDA figures stand at -$65.8 million (Q1 2026), -$83.5 million (Q4 2025), and -$94.4 million (Q3 2025).